According to a Reuters article, the German pharma company Bayer is cooperating with Credit Suisse to search for potential buyers of its diabetes device business.The news page quotes anonymous sources saying that Bayer wants to focus on sectors with higher margins and therefore plans to dispose of the unit. Bayer is in the middle of a large scale restructuring process. In May, the company bought Merck’s consumer health drug business for 10.4b euros in the second biggest acquisition in its corporate history. CEO Marijn Dekkers said that he wants Bayer to become the world’s market leader in over-the-counter drugs. Dekkers told the Financial Times that the company is looking for further acquisitions. “I think in OTC we’re going to see more consolidation there. We believe that critical mass is important. You need to be a large player there. If you don’t participate in consolidation you fall behind, and that is competitively dangerous.” To realize this goal, Dekkers needs money for further acquisitions. The company had announced in September that it would float its plastics unit Bayer Material Science by 2016. In May, Bayer HealthCare sold its interventional device business to the American competitor Boston Scientific for approximately EUR 300m. In 2012, Bayer tried unsuccessfully to sell its blood glucose meter business.Bloomberg has spoken to anonymous insiders who speculate that private-equity companies Cinven Ltd., EQT Partners AB, KKR & Co. (KKR) and Triton Advisers might be potential buyers. According to this report, the unit could be worth between 1 and 2 billion euros. The unit reported sales of more than 700 million euros in 2013.